Literature DB >> 10224160

VLDL activation of plasminogen activator inhibitor-1 (PAI-1) expression: involvement of the VLDL receptor.

L Nilsson1, M Gåfvels, L Musakka, K Ensler, D K Strickland, B Angelin, A Hamsten, P Eriksson.   

Abstract

The potential role of the very low density lipoprotein (VLDL) receptor in mediating VLDL-induced plasminogen activator inhibitor-1 (PAI-1) expression was studied in vitro. Cultured endothelial cells incubated with VLDL showed an increased secretion of PAI-1. This response to VLDL could be completely prevented by the receptor-associated protein (RAP) and partially blocked by rabbit polyclonal anti-VLDL receptor IgG. Furthermore, Chinese hamster ovary (CHO) control cells and cells overexpressing the VLDL receptor were transiently transfected with a PAI-1 promoter-reporter construct and incubated with VLDL. The PAI-1 promoter activity in response to VLDL was significantly higher in the VLDL receptor overexpressing cells compared to the control cells. Addition of RAP completely blocked the VLDL-activated PAI-1 transcription. Electromobility shift assay was performed to investigate whether the enhanced PAI-1 promoter activity seen in the VLDL receptor overexpressing cells in response to VLDL involved induction of the previously described VLDL-inducible factor(s) binding to the -675 to -653 region of the PAI-1 promoter. We found that the binding of the VLDL-inducible factor in VLDL receptor overexpressing cells was markedly enhanced by addition of VLDL as compared to control cells where no increased binding could be seen in response to VLDL. In summary, these results indicate that the VLDL receptor is a strong candidate for mediating VLDL effects on PAI-1 synthesis and secretion in cells expressing this receptor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10224160

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  5 in total

1.  Significant inverse associations of serum n-6 fatty acids with plasma plasminogen activator inhibitor-1.

Authors:  Sunghee Lee; J David Curb; Takashi Kadowaki; Rhobert W Evans; Katsuyuki Miura; Tomoko Takamiya; Chol Shin; Aiman El-Saed; Jina Choo; Akira Fujiyoshi; Teruo Otake; Sayaka Kadowaki; Todd Seto; Kamal Masaki; Daniel Edmundowicz; Hirotsugu Ueshima; Lewis H Kuller; Akira Sekikawa
Journal:  Br J Nutr       Date:  2011-08-16       Impact factor: 3.718

2.  Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis.

Authors:  Mark M Smits; Pier Woudstra; Kristina M Utzschneider; Jenny Tong; Fernando Gerchman; Mirjam Faulenbach; Darcy B Carr; Kathryn Aston-Mourney; Alan Chait; Robert H Knopp; James B Meigs; Edward J Boyko; Steven E Kahn
Journal:  Ann Epidemiol       Date:  2013-03-25       Impact factor: 3.797

3.  Relationships of PAI-1 levels to central obesity and liver steatosis in a sample of adult male population in southern Italy.

Authors:  Antonio Barbato; Roberto Iacone; Giovanni Tarantino; Ornella Russo; Paolo Sorrentino; Sonia Avallone; Ferruccio Galletti; Eduardo Farinaro; Elisabetta Della Valle; Pasquale Strazzullo
Journal:  Intern Emerg Med       Date:  2009-04-07       Impact factor: 3.397

4.  Association between Plasma Levels of Plasminogen Activator Inhibitor-1 and Colorectal Neoplasms.

Authors:  Eun Ran Kim; Mun Hee Yang; Yeun Jung Lim; Jin Hee Lee; Dong Kyung Chang; Young-Ho Kim; Hee Jung Son; Jae J Kim; Jong Chul Rhee; Jin Yong Kim
Journal:  Gut Liver       Date:  2013-06-11       Impact factor: 4.519

5.  Plasminogen activator inhibitor-1 4G/5G gene polymorphism and primary open-angle glaucoma.

Authors:  Georg Mossböck; Martin Weger; Christoph Faschinger; Otto Schmut; Wilfried Renner
Journal:  Mol Vis       Date:  2008-07-04       Impact factor: 2.367

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.